Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
IV gentamicin improves epidermolysis bullosa
Key clinical point: IV gentamicin improves wound closure in patients with recessive dystrophic EB due to nonsense mutations.
Major finding: Expression of functional collage type VII at the dermal-epidermal junction was significantly enhanced in response to IV gentamicin.
Study details: This was an open-label phase 1/2 study including 4 patients with recessive dystrophic epidermolysis bullosa due to nonsense mutations who were treated with IV gentamicin.
Disclosures: The presenter reported having no financial conflicts regarding the study, supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the EB Research Partnership, and the EB Research Foundation.
Hao M et al. AAD 2020. LBCT.